Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

uPET

Financiado

Cerrado

Molecular imaging and targeted therapy of the aggressive phenotype development...

Molecular imaging and targeted therapy of the aggressive phenotype development of uPAR theranostics for cancer patients For practice of personalized medicine in cancer, non-invasive tools for diagnosing at the molecular level are needed. Molecular imaging methods are capable of this while at the same time circumventing sampling error as the whole t... ver más

31/03/2021

REGIONH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

REGION HOVEDSTADEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-03-31

ERC-ADG-2014: ERC Advanced Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

REGIONH

2.07M€ | Lider

YSENGINEERS

321.19K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ImageLink Multiparametric tumor imaging and beyond Towards understand... 2M€ Cerrado

ONQVIEW Non Radioactive Molecular Imaging Driven Drug Development in... 2M€ Cerrado

TAcTIC TArgeTed molecular Imaging and surgery for gastro intestinal... 150K€ Cerrado

ILLUMINATE INCREASING LUTETIUM PRODUCTION, WHILE LEVERAGING METABOLIC I... 19M€ Cerrado

HYPMED Digital Hybrid Breast PET MRI for Enhanced Diagnosis of Brea... 6M€ Cerrado

SAF2008-03323 IMAGEN MOLECULAR Y DE FENOTIPO DE LA PROGRESION TUMORAL CERE... 150K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2015-09-07
Fecha Fin: 2021-03-31

Líder del proyecto

REGION HOVEDSTADEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto For practice of personalized medicine in cancer, non-invasive tools for diagnosing at the molecular level are needed. Molecular imaging methods are capable of this while at the same time circumventing sampling error as the whole tumor burden is evaluated. We recently developed and performed the first-ever clinical PET scan of uPAR, a proteolytic system known to be strongly associated with metastatic potential in most cancer forms. We believe this new concept of uPAR-PET is a major breakthrough and has the potential to become one of the most used PET tracers as it fulfils unmet needs in prostate and breast cancer. Based on this, together with additional proof-of-concept data we obtained on targeting uPAR for optical imaging and radionuclide therapy, we now plan to develop and take into patients these new technologies for improved outcome. Specific aims are to develop and translate into human use: 1. A PET uPAR imaging ligand platform for visualization of the aggressive phenotype and risk-stratification to be used in tailoring therapy, e.g. in prostate cancer to decide whether prostatectomy is necessary. 2. uPAR-PET combined with simultaneous 13C-hyperpolarized pyruvate MRSI (Warburg effect). This will increase prognostic power, refine tumor phenotyping and thereby allow for better tailoring of therapy and early prediction of treatment response. 3. A uPAR optical imaging technology for guiding removal of cancer tissue during surgery. This will help delineate cancer tissue for removal while leaving healthy tissue behind. We expect better outcome with removal of less tissue. 4. Selective radionuclide therapies targeting uPAR positive, invasive cancer cells using β or α emitters. Dose planning will be performed using uPAR-PET imaging. This image-therapy pairing is also known as theranostics. Our endeavour is ambitious, yet realistic considering our competencies and track-record. We expect cancer patients to benefit from our new methods within the 5 year time-frame.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores